{"id":464721,"date":"2021-03-24T20:56:25","date_gmt":"2021-03-25T00:56:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464721"},"modified":"2021-03-24T20:56:25","modified_gmt":"2021-03-25T00:56:25","slug":"azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/","title":{"rendered":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy"},"content":{"rendered":"

<\/p>\n

AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy<\/b><\/p>\n

76% vaccine efficacy against symptomatic COVID-19<\/i><\/b><\/p>\n

100% efficacy against severe or critical disease and hospitalization<\/i><\/b><\/p>\n

85% efficacy against symptomatic COVID-19 in participants aged 65 years and over<\/i><\/b><\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE<\/a>)–
\nPositive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021.\n<\/p>\n

\nThese results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks.\n<\/p>\n

\nThis primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis. Participants were randomized on a 2:1 ratio between the vaccine and placebo group.\n<\/p>\n

\nThe primary endpoint, vaccine efficacy at preventing symptomatic COVID-19 was 76% (confidence interval (CI): 68% to 82%) occurring 15 days or more after receiving two doses given four weeks apart. In addition, results were comparable across age groups, with vaccine efficacy of 85% (CI: 58% to 95%) in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalization, demonstrated 100% efficacy. There were eight cases of severe COVID-19 observed in the primary analysis with all of those cases in the placebo group.\n<\/p>\n

\nThe vaccine was well tolerated, and no safety concerns related to the vaccine were identified.\n<\/p>\n

\nMene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: \u201cThe primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over. We look forward to filing our regulatory submission for Emergency Use Authorization in the US and preparing for the rollout of millions of doses across America.\u201d\n<\/p>\n

\nThere were 190 cases in the primary analysis. There are 14 additional possible or probable cases to be adjudicated so the total number of cases and the point estimate may fluctuate slightly.\n<\/p>\n

\nAstraZeneca will also submit the primary analysis for peer-reviewed publication in the coming weeks.\n<\/p>\n

D8110C00001<\/b><\/p>\n

\nThe US Phase III trial, called D8110C00001, was led by AstraZeneca and funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS) in collaboration with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Army Contracting Command, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial.\n<\/p>\n

\nD8110C00001 is a randomized, double-blind, placebo-controlled multicenter Phase III trial assessing the safety, efficacy, and immunogenicity of AZD1222 compared to placebo for the prevention of COVID-19, in 32,449 participants across 88 trial centers in the US, Peru and Chile. Trial participants aged 18 years or over who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus and COVID-19 were randomized in a 2:1 ratio to receive two intramuscular doses of either 5 x1010<\/sup> viral particles of AZD1222 or saline placebo four weeks apart.\n<\/p>\n

\nThe pre-specified statistical analysis plan required at least 75 adjudicated cases at interim analysis, and at least 150 adjudicated cases at primary analysis.\n<\/p>\n

AZD1222<\/b><\/p>\n

\nAZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.\n<\/p>\n

\nIn May 2020, AstraZeneca received<\/a> support of more than $1bn from BARDA for the development, production and delivery of the vaccine under an agreement with the US Department of Defense\u2019s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. The Phase III D8110C00001 trial is part of this funding agreement.\n<\/p>\n

\nThe vaccine has been granted a conditional marketing authorization or emergency use in more than 70 countries across six continents, and with the Emergency Use Listing granted by the World Health Organization this accelerates the pathway to access in up to 142 countries through the COVAX Facility.\n<\/p>\n

BARDA, ASPR, HHS<\/strong><\/p>\n

\nHHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR<\/a> is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA<\/a> invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures \u2013 vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. The AstraZeneca vaccine candidate is one of six BARDA is supporting in development and manufacturing, and the third BARDA-supported SARS-COVD-2 vaccine supported to successfully complete a large Phase III trial. To learn more about BARDA\u2019s support for the COVID-19 pandemic response, visit medicalcountermeasures.gov<\/a>.\n<\/p>\n

JPEO-CBRND<\/b><\/p>\n

\nAs part of the Department of Defense, JPEO-CBRND protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological and nuclear (CBRN) threats. JPEO-CBRND\u2019s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. JPEO-CBRND facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats such as COVID-19. To learn more about JPEO-CBRND\u2019s COVID-19 response, visit https:\/\/www.jpeocbrnd.osd.mil\/coronavirus<\/a>.\n<\/p>\n

NIAID and the CoVPN<\/b><\/p>\n

\nThe CoVPN was formed by the NIAID at the US National Institutes of Health, part of the US Department of Health and Human Services, to respond to the global pandemic. Through the CoVPN, NIAID is leveraging the infectious disease and community engagement expertise of its existing research networks and global partners to address the pressing need for vaccines and antibodies against the SARS-CoV-2 virus. CoVPN will work to develop and conduct studies to ensure rapid and thorough evaluation of vaccines and antibodies for the prevention of COVID-19.\n<\/p>\n

About AstraZeneca<\/b><\/p>\n

\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com<\/a> and follow us on Twitter @AstraZenecaUS<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210324006015\/en\/<\/a><\/span><\/p>\n

Media Inquiries
\n<\/b>
Michele Meixell +1 302 885 2677
\n
Abigail Bozarth +1 302 885 2677\n<\/p>\n

KEYWORDS:<\/b> Delaware United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Medical Supplies Biotechnology FDA Health General Health Pharmaceutical Research Infectious Diseases Hospitals Science Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy 76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization 85% efficacy against symptomatic COVID-19 in participants aged 65 years and over WILMINGTON, Del.–(BUSINESS WIRE)– Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks. This primary efficacy … <\/p>\n

Continue reading “AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464721","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy 76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization 85% efficacy against symptomatic COVID-19 in participants aged 65 years and over WILMINGTON, Del.–(BUSINESS WIRE)– Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks. This primary efficacy … Continue reading "AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-25T00:56:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy\",\"datePublished\":\"2021-03-25T00:56:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/\"},\"wordCount\":1163,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/\",\"name\":\"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-25T00:56:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/","og_locale":"en_US","og_type":"article","og_title":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk","og_description":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy 76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization 85% efficacy against symptomatic COVID-19 in participants aged 65 years and over WILMINGTON, Del.–(BUSINESS WIRE)– Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks. This primary efficacy … Continue reading \"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-25T00:56:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy","datePublished":"2021-03-25T00:56:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/"},"wordCount":1163,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/","name":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-25T00:56:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210324006015r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464721"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464721\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}